

07:30-08:30 **Pre-Congress** Sponsored Breakfast Symposium

08:30-10:00 **OPENING SESSION**  
Big Controversies in Retina in 2023

Chairs: Baruch Kuppermann, *USA*; Anat Loewenstein, *Israel*; Rufino Silva, *Portugal*

08:30-08:40 **Opening Remarks**  
Baruch Kuppermann, *USA*; Anat Loewenstein, *Israel*; Rufino Silva, *Portugal*

08:40-09:00 **Keynote Lecture**

08:40-08:55 Translating discoveries at the molecular level to new therapies for eye diseases: The Institute of Molecular and Clinical Ophthalmology Basel (IOB)  
Hendrik Scholl, *Switzerland*

08:55-09:00 Q&A

09:00-09:30 **Debate 1:** In 5 years we will abandon clinical examination for telemedicine and AI assisted decisions

09:00-09:10 **Yes:** Ursula Schmidt-Erfurth, *Austria*

09:10-09:20 **No:** Manuel Falcão, *Portugal*

09:20-09:30 Discussion

09:30-10:00 **Debate 2:** Complement inhibition is a game changer in the management of patients with geographic atrophy

09:30-09:40 **Yes:** Peter K. Kaiser, *USA*

09:40-09:50 **No:** Ursula Schmidt-Erfurth, *Austria*

09:50-10:00 Discussion

10:00-10:30 **Visit Exhibition, Posters & Coffee and Refreshment Break**

## HALL A

10:30-12:00

**MEDICAL RETINA 1**  
Neovascular ("Wet") AMD Management*Chairs:* Rufino Silva, Portugal; Antonio Campos, Portugal

10:30-11:00

**Debate 1:** Durability associated with multi target therapies is superior to anti-VEGF mono-target therapy in AMD

10:30-10:40

**Yes:** Anat Loewenstein, Israel

10:40-10:50

**No:** Antonio Campos, Portugal

10:50-11:00

Discussion

11:00-11:30

**Debate 2:** Higher doses of existing intravitreal drugs can be beneficial in the management of nAMD

11:00-11:10

**Yes:** Peter K. Kaiser, USA

11:10-11:20

**No:** Michaella Goldstein, Israel

11:20-11:30

Discussion

11:30-12:00

**Debate 3:** Presence of macular neovascularization on OCTA is predictive of subsequent exudation

11:30-11:40

**Yes:** Angela Carneiro, Portugal

11:40-11:50

**No:** Stephan Michels, Switzerland

11:50-12:00

Discussion

12:15-13:15

**Industry Sponsored Luncheon Symposium**  
*Lunch boxes served 12:00-12:15*

13:15-13:45

**Visit Exhibition, Posters & Dessert Break**

13:45-15:15

**SURGICAL RETINA 1****Controversial Approaches to Common Surgical Questions***Chairs: William F. Mieler, USA; Stanislao Rizzo, Italy, Stratos Gotzaridis, Greece***13:45-14:15****Debate 1:** Vitrectomy is safe and beneficial in the management of significant vitreous opacities

13:45-13:55

**Yes:** Francesco Boscia, *Italy*

13:55-14:05

**No:** William F. Mieler, *USA*

14:05-14:15

Discussion

**14:15-14:45****Debate 2:** In epiretinal membrane surgery, removal of the ILM is essential

14:15-14:25

**Yes:** João Figueira, *Portugal*

14:25-14:35

**No:** Francesco Boscia, *Italy*

14:35-14:45

Discussion

**14:45-15:15****Debate 3:** The preferred procedure for a large refractory macular hole is autologous retinal transplantation?

14:45-14:55

**Yes:** Stanislao Rizzo, *Italy*

14:55-15:05

**No:** José Maria Ruiz-Moreno, *Spain*

15:05-15:15

Discussion

## HALL A

**15:15-16:15** **VISION ACADEMY IN RETINA 2023**  
Controversies in the Management of Intravitreal Therapy for Retinal Diseases  
*Chairs:* Baruch Kuppermann, *USA*; Anat Loewenstein, *Israel*

**15:15-15:20** Welcome and Introductions:  
Anat Loewenstein, *Israel*

**15:20-15:35** **Debate 1:** Optimal application of anti-VEGFs: Do we need to reconsider our treatment paradigms?

15:20-15:25 **Yes:** Bora Eldem, *Turkey*

15:25-15:30 **No:** Robert Finger, *Germany*

15:30-15:35 Presentation of Viewpoint:  
Anat Loewenstein, *Israel*

**15:35-15:50** **Debate 2:** Should we be concerned about IOP elevation after IVTs?

15:35-15:40 **Yes:** Polona Jaki Mekjavic, *Slovenia*

15:40-15:45 **No:** Sobha Sivaprasad, *UK*

15:45-15:50 Presentation of Viewpoint:  
Anat Loewenstein, *Israel*

**15:50-16:10** Panel discussion / Audience Q&A

**16:10-16:15** Summary and Close:  
Anat Loewenstein, *Israel*

**16:15-17:15** Industry Sponsored Symposium

**17:15-18:15** "Happy Hour" Cocktail

## HALL A

07:30-08:30 Industry Sponsored Breakfast Symposium

HALL A

08:30-10:00 **MEDICAL RETINA 2**  
Diabetic Macular Edema (DME) and Proliferative Diabetic Retinopathy

*Chairs:* Paolo Lanzetta, *Italy*;  
José Cunha-Vaz, *Portugal*;  
Francesco Bandello, *Italy*

08:30-09:00 **Debate 1:** Can biomarkers be used to determine if steroids vs anti-VEGF agents are more appropriate to treat DME?

08:30-08:40 **Yes:** Lilianne Duarte, *Portugal*

08:40-08:50 **No:** Sobha Sivaprasad, *UK*

08:50-09:00 Discussion

09:00-09:30 **Debate 2:** Is treatment of NPDR with pharmacotherapy warranted at this time?

09:00-09:10 **Yes:** Sobha Sivaprasad, *UK*

09:10-09:20 **No:** José Cunha-Vaz, *Portugal*

09:20-09:30 Discussion

09:30-10:00 **Debate 3:** Multi target therapies is superior to anti-VEGF mono-target therapy in DME

09:30-09:40 **Yes:** Lilianne Duarte, *Portugal*

09:40-09:50 **No:** Patricia Udaondo, *Spain*

09:50-10:00 Discussion

10:00-10:30 Visit Exhibition, Posters & Coffee and Refreshment Break

## HALL B

08:30-10:00 **NEURO-OPHTHALMOLOGY 1**  
The Afferent Pathway

*Chair:* Andrew G. Lee, *USA*

08:30-09:00 **Debate 1:** Should all patients with thyroid eye disease be offered teprotumumab?

08:30-08:40 **Yes:** Pedro Fonseca, *Portugal*

08:40-08:50 **No:** Andrew G. Lee, *USA*

08:50-09:00 Discussion

09:00-09:30 **Debate 2:** Should patients with giant cell arteritis be offered tocilizumab?

09:00-09:10 **Yes:** John Chen, *USA*

09:10-09:20 **No:** Susan Mollan, *UK*

09:20-09:30 Discussion

09:30-10:00 Case Presentations

*Moderator:* John Chen, *USA*

*Panelists:* All Speakers

Andrew G. Lee, *USA*;

Pedro Fonseca, *Portugal*;

Susan Mollan, *UK*

## HALL A

10:30-12:00

**MEDICAL RETINA 3**  
AMD and Hereditary Retinal Degeneration Topics*Chairs:* Hendrik Scholl, *Switzerland*;  
Angela Carneiro, *Portugal*;  
Marco Dutra Medeiros, *Portugal*

10:30-11:00

**Debate 1:** Retinal implant is still a future option for patients with hereditary retinal degeneration

10:30-10:40

**Yes:** William F. Mieler, *USA*

10:40-10:50

**No:** Hendrik Scholl, *Switzerland*

10:50-11:00

Discussion

11:00-11:30

**Debate 2:** Home monitoring will be an important management option for our patients with AMD

11:00-11:10

**Yes:** Rufino Silva, *Portugal*

11:10-11:20

**No:** Robert Finger, *Germany*

11:20-11:30

Discussion

11:30-12:00

**Debate 3:** Suprachoroidal injection of a viral vector expressing an anti-VEGF protein is a viable treatment option for the management of retinal disease

11:30-11:40

**Yes:** Marco Dutra Medeiros, *Portugal*

11:40-11:50

**No:** William F. Mieler, *USA*

11:50-12:00

Discussion

12:15-13:15

Industry-Sponsored Luncheon Symposium

*Lunch boxes served 12:00-12:15*

HALL A

13:30-14:30

Industry-Sponsored Dessert Symposium

*Dessert boxes served 13:15-13:30*

HALL A

14:30-15:00

Visit Exhibition, Posters &amp; Coffee and Refreshment Break

## HALL B

10:30-12:00

**UVEITIS 1***Chairs:* Bahram Bodaghi, *France*;  
Zohar Habet-Wilner, *Israel*

10:30-11:00

**Debate 1:** Intravitreal corticosteroids for the treatment of uveitic macular edema is better (or similar) than systemic treatment

10:30-10:40

**Yes:** Aniruddha Agarwal, *UAE*

10:40-10:50

**No:** Sarah Touhami, *France*

10:50-11:00

Discussion

11:00-11:30

**Debate 2:** Vitrectomy should be performed in patients with ARN syndrome

11:00-11:10

**Yes:** Sarah Touhami, *France*

11:10-11:20

**No:** Luis Figueira, *Portugal*

11:20-11:30

Discussion

11:30-12:00

**Debate 3:** Systemic antibiotic treatment is mandatory for ocular toxoplasmosis

11:30-11:40

**Yes:** Aniruddha Agarwal, *UAE*

11:40-11:50

**No:** Zohar Habet-Wilner, *Israel*

11:50-12:00

Discussion

## HALL A

**15:00-16:30** **SURGICAL RETINA 2**  
Controversies in the Utilization of Cutting Edge Vitreoretinal Surgical Technology

*Chairs:* João Figueira, *Portugal*;  
José Maria Ruiz-Moreno, *Spain*

**15:00-15:30** **Debate 1:** Digital, heads up imaging in the operating room has led to improvement in surgical outcomes

**15:00-15:10** **Yes:** Angelina Meireles, *Portugal*

**15:10-15:20** **No:** José Maria Ruiz-Moreno, *Spain*

**15:20-15:30** Discussion

**15:30-16:00** **Debate 2:** Surgical intraoperative OCT is practical in VR surgery

**15:30-15:40** **Yes:** Carlos Marques Neves, *Portugal*

**15:40-15:50** **No:** Angelina Meireles, *Portugal*

**15:50-16:00** Discussion

**16:00-16:30** **Debate 3:** Early surgery in myopic maculopathy versus delayed surgery

**16:00-16:10** **Yes:** Jorge Ruiz-Medrano, *Spain*

**16:10-16:20** **No:** Stratos Gotzaridis, *Greece*

**16:20-16:30** Discussion

## HALL B

**15:00-16:30** **NEURO-OPHTHALMOLOGY 2**  
The Efferent Pathway and Systemic Disorders

*Chair:* Andrew G. Lee, *USA*

**15:00-15:30** **Debate 1:** Patients with NMO be offered eculizumab?

**15:00-15:10** **Yes:** John Chen, *USA*

**15:10-15:20** **No:** Susan Mollan, *UK*

**15:20-15:30** Discussion

**15:30-16:00** **Debate 2:** All patients with optic neuritis should have both NMO and MOG testing?

**15:30-15:40** **Yes:** Pedro Fonseca, *Portugal*

**15:40-15:50** **No:** Andrew G. Lee, *USA*

**15:50-16:00** Discussion

**16:00-16:30** Case Presentations

*Moderator:* John Chen, *USA*

*Panelists:* All Speakers

Andrew G. Lee, *USA*;

Susan Mollan, *UK*;

Pedro Fonseca, *Portugal*

## HALL A

16:30-18:00

**MEDICAL RETINA 4**  
New Treatment Strategies*Chairs:* Rufino Silva, Portugal;  
Patricia Udaondo, Spain

16:30-17:00

**Debate 1:** Biosimilars will become the primary treatment option for retinal diseases

16:30-16:40

**Yes:** Ashish Sharma, India

16:40-16:50

**No:** Paolo Lanzetta, Italy

16:50-17:00

Discussion

17:00-17:30

**Debate 2:** Continuous delivery with the Port Delivery System is an important treatment option for patients with nAMD

17:00-17:10

**Yes:** Rita Flores, Portugal

17:10-17:20

**No:** Patricia Udaondo, Spain

17:20-17:30

Discussion

17:30-18:00

**Debate 3:** Sub-retinal viral vector gene therapy delivery of anti-VEGF is a viable management option for the management of retinal disease

17:30-17:40

**Yes:** João Figueira, Portugal

17:40-17:50

**No:** Paolo Lanzetta, Italy

17:50-18:00

Discussion

## HALL B

16:30-18:00

**UVEITIS 2***Chairs:* Bahram Bodaghi, France;  
Zohar Habet-Wilner, Israel

16:30-17:00

**Debate 1:** Vogt Koyanagi Harada: Immunomodulatory treatment should be started at the first manifestation of VKH alongside with systemic corticosteroids

16:30-16:40

**Yes:** Ines Leal, Portugal

16:40-16:50

**No:** Bahram Bodaghi, France

16:50-17:00

Discussion

17:00-17:30

**Debate 2:** Cataract surgery in JIA-uveitis: leaving the child aphakic

17:00-17:10

**Yes:** Ines Leal, Portugal

17:10-17:20

**No:** Bahram Bodaghi, France

17:20-17:30

Discussion

17:30-18:00

**Debate 3:** Intraocular corticosteroids may be used for infectious uveitis

17:30-17:40

**Yes:** Luis Figueira, Portugal

17:40-17:50

**No:** Zohar Habet-Wilner, Israel

17:50-18:00

Discussion